This is a lecture that will cover the recent chest pain guidelines update and what EKG findings are now STEMI equivalents and what findings need emergent cath. This is designed for any practice setting who has chest pain complaints.

1. Recognize Dewinters T waves on the EKG and why they are dangerous.
2. Identify Wellens T waves and what they mean. 
3. Describe the 5 findings that will be read as nonspecific but mean that there is a left anterior descending artery occlusion. 

Chronic kidney disease (CKD) represents a substantial health burden for a sizeable proportion of the US population. Nearly 40 million adults are estimated to be affected. Despite advances in strategies for managing patients with CKD, many patients still have residual risk of kidney disease progression and elevated cardiovascular risk. Newer therapies for CKD and DKD, including sodium-glucose cotransporter-2 (SGLT-2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs), have recently been incorporated into evidence-based guidelines, representing substantial shifts in the treatment paradigm.

At the end of the presentation, participants will be able to: 

1. Detect and recognize CKD in patients with reduced kidney function to improve opportunities for early intervention. 
2. Implement screening for albuminuria in patients with diabetes in clinical practice to identify CKD as early as possible. 
3. Initiate therapy with evidence-based therapies, including SGLT-2 inhibitors and nonsteroidal MRAs, for patients with DKD when indicated. 
4. Compare and contrast differences between steroidal MRAs and nonsteroidal MRAs, including physiologic effects, therapeutic indications, and clinical outcomes.

The incidental discovery of suspected fatty liver disease based upon routine laboratory results and/or imaging is one of the most common reasons for primary care referrals to Gastroenterology specialists. With increased knowledge on how to exclude additional hepatic disease as well as potential complications and monitoring parameters, many cases of fatty liver disease can be managed within the spectrum of primary care, resulting in decreased emotional and financial burden on patients.  At the end of this session, attendees will be able to: 

1. Recognize risk factors for the development and progression of fatty liver disease, including both alcoholic and non-alcoholic etiologies.
2. Discuss the approach to diagnostic testing to further evaluate potential fatty liver as well as exclude other underlying hepatic pathology.
3. Review indications which warrant referral to a specialist.
4. Summarize the most important aspects of patient education as it relates to the improvement and prevention of progression of fatty liver.

Thirty Million Americans, and 400 million people world wide have COPD.  Yet half of them have never been diagnosed.  How can this be the 3rd most common chronic condition, 3rd leading cause of admission, and 3rd leading cause of death, ... yet be hidden in plain site.  Healthcare providers on the front lines have the opportunity to ask the question, 'Could this be COPD?', and crack the code on the invisible epidemic.  At the end of this activity, learners will be able to: 

1. Recognize patients at high risk for COPD
2. Iidentify screening tools and methods to confirm their index of suspicion.
3. Lead a 'find the missing millions' in their place of service.
4. Advise patients where they should or could go next for confirmatory testing, and more information.
5. Identify social determinants of health that predispose patients to the risk of COPD.